Are Natriuretic Peptides Clinically Useful as Markers of Heart Failure?

Gu J D'Andrea M Seethapathy M. Atrial natriuretic peptide and its messenger ribonucleic acid in overloaded and overload-released ventricles of rat. Endocrinology 1989;125: 2066–74.

Saito Y Nakao K Arai H Nishimura K Okumura K Ubata K Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989;125: 298–305.

Schulz-Knappe P Forssman K Herbst F Hock D Pipkorn R Forssman WG . Isolation and structural analysis of ‘urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66: 752–9.

Maack T Suzuki M Almeida FA Nussenzveig D Scarborough RM McEnroe GA . Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238: 675–8.

Koller KJ Goeddel DV . Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86: 1081–8.

Hunt PJ Espiner EA Nicholls MG Richards AM Yandle TG . Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996;81: 3871–6.

Schultz HD Gardner DG Deschepper CF Coleridge HM Coleridge JC . Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol 1988;155: R6–R13.

Yang RH Jin HK Wyss JM Chen YF Oparil S. Pressor effect of blocking atrial natriuretic in nucleus tractus solitarii. Hypertension 1992;19: 198–205.

Itoh H Pratt RE Dzau VJ . Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86: 1690–7.

Furuya M Aisaka K Miyazaki T Honbou N Kawashima K Ono T C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun 1993;193: 248–53.

Marin-Grez M Fleming JT Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature 1986;324: 473–6.

Levin ER . Natriuretic peptides. N Engl J Med 1998;339: 321–8.

Lappe RW Smits JF Todt JA Debets JJ Wendt RL . Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. Circulation Res 1985;56: 606–12.

Angeli P Jimenez W Arroyo V Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994;20: 948–54.

Valdivieso A. The kidney in chronic liver disease: use of natriuretic peptides. Biol Res 1998;31: 291–304.

Zhang PL Mackenzie HS Troy JL Brenner BM . Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 1994;4: 1564–70.

Levin ER Isackson PJ Hu RM . Endothelin increases atrial natriuretic peptide production in cultured rat diencephalic neurons. Endocrinology 1991;128: 2925–30.

Levin ER Hu RM Rossi M Pickart M. Arginine vasopressin stimulates atrial natriuretic peptide gene expression and secretion from rat hypothalamic diencephalic neurons. Endocrinology 1992;131: 1417–23.

Steele MK Gardner DG Xie PL Schultz HD . Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow. Am J Physiol 1991;260: R475–9.

Langub MC Jr Dolgas CM Watson RE Jr Hermann JP . The C-type natriuretic peptide receptor is the predominant natriuretic peptide receptor mRNA expressed in rat hypothalamus. J Neuroendocrinal 1995;7: 305–9.

Buckley MG Marcus NJ Yacoub MH . Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999;97: 689–95.

Lerman A Gibbons RJ Rodeheffer RJ Bailey KR McKinley J Heublein DM Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet 1993;341: 1109–13.

Nielsen OW Fischer JF Hilden J Larsen CT Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross-sectional study evaluating a range of diagnostic tests. BMJ 2000;320: 220–4.

Hara H Ogihara T Shima J Saito H Rabugi H Plasma atrial natriuretic peptide level as an index for the severity of congestive heart failure. Clin Cardiol 1987;10: 437–42.

Pfeffer MA Braunwald E Moye LA Basta L Brown EJJ Cuddy TE Effect of captopril on mortality and morbidity in patients with reduced LV function after myocardial infarction. N Engl J Med 1992;327: 669–77.

Hall C Rouleau JL Moye L deChamplain J Bichet D Klein M N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89: 1934–42.

Yu CM Sanderson JE Shum IO Chan S Yeung LY Hung YT Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996;17: 1694–1702.

Dickstein K Abrahamsen S Aarsland T. Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure. Scand Cardiovasc J 1998;32: 361–1.

Motwani JG McAlpine H Kennedy N Struthers AD . Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;34: 1109–13.

Davidson NC Naas A Hanson JK Kennedy NS Coutie WJ Struthers AD Comparison of atrial natriuretic peptide, B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic function. Am J Cardiol 1996;77: 828–31.

Omland T Aakvaag A Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76: 232–7.

Yamamoto K Burnett JC Jougaski M Nishimura RA Bailey KR Saito Y Superiority of BNP as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28: 988–94.

Friedl W Mair J Thomas S Pichler M Puschendorf B. Natriuretic peptides and cGMP in asymptomatic and symptomatic left ventricular dysfunction. Heart 1996;76: 129–36.

Yamada Y Goto J Yokota M. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. Cardiology 1997;88: 401–7.

Cowie MR Struthers AD Wood DA Coats AJS Thompson SG Poole-Wilson PA Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350: 1347–51.

McDonagh TA Robb SD Murdoch DR Morton JJ Ford J Morrison CE Biochemical detection of left ventricular systolic dysfunction. Lancet 1997;351: 9–13.

Sumida H Yasue H Yoshimura M Okumura K Ogawa H Kugiyama K Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 1995;25: 1105–10.

Tsutamato T Maeda Y Wada A Plasma brain natriuretic peptide concentration as a prognostic predictor in patients with chronic congestive heart failure. Circulation 1988;(Suppl 4.2): 321–2.

Tsutamoto T Wada A Maeda K Hisanga T Maeda Y Fukai D Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 1997;96: 509–16.

Darbar D Davidson NC Gillespie N Choy AM Lange CC Shyr Y Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 1996;78: 284–7.

Arakawa N Nakamura M Aoki H Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27: 1656–61.

Omland T Aakvaag A Bonarjee VVS Caidahl K Lie RT Nilsen DW Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction. Circulation 1996;93: 1963–9.

Selvais PL Donckier JE Robert A Laloux O Van-Linden F Ahn S Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest 1998;28: 636–42.

Richards AM Nicholls MG Yandle TG Ikram H Espiner EA Turner JG Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999;81: 114–20.

Hono T Kohno M Takeda T. Cosecretion of atrial and brain natriuretic peptides stimulated by endothelin-1 from cultured rat atrial and ventricular cardiocytes. Metabolism 1993;42: 94–6.

McMurray JJ Ray SG Abdullah I Dargie HJ Morton JJ . Plasma endothelin in chronic heart failure. Circulation 1992;85: 1374–9.

Choy AM Darbar D Lang CC Pringle T McNeill G Kennedy N Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic and neurohormonal methods. Br Heart J 1994;72: 16–22.

Richards AM Nicholls MG Yandle TG Frampton C Espiner EA Turner JG Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97: 1921–9.

Talwar S Squire IB Davies JE Barnett DB Ng LL . Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left ventricular systolic dysfunction in a high risk population. Eur Heart J 1999;20: 1736–44.

Struthers AD . Effect of ACE inhibitors on the atrial natriuretic peptides in heart failure. Br Heart J 1994;72: 504.

Northridge DB Newby DE Rooney E Norrie J Dargie HJ . Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999;138: 1149–57.

Sanderson JE Chan WW Hung YT Chan SK Shum JO Raymond K Effects of low dose betablockers on atrial and ventricular (B-type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating betablocker. Br Heart J 1995;74: 502–7.

Tsutamato T Wada A Maeda K Hisanga T Fukai D Maeda Y Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 1997;134 (5 Pt 1): 910–6.

Koon J Hope J Garcia A Kasanegra R Gardetto N DeMaria A A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography. J Am Coll Cardiol 2000;35 (Suppl A): 419.

Murdoch DR McDonagh TA Byrne J Blue L Farmer R Morton JJ Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138: 1126–32.

Struthers AD . How to use natriuretic peptides levels for diagnosis and prognosis. Eur Heart J 1999;20: 1374–5.

Fruhwald FM Fahrleitner A Watzinger S Fruhald S Dobnig H Schumacher M Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999;20: 1415–23.

Davie AP Francis CM Love MP Caruama L Starkey IR Shaw TR Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J 1996;312: 222.

Kelly R McWalter R Stonebridge P Tunstall-Pedoe H Struthers AD . Should we screen for treatable left ventricular systolic dysfunction in patients who present with their first stroke, transient ischaemic attack or peripheral vascular disease? Eur Heart J 2000;Suppl 21: 1629.

Badgett RG Mulrow CD Otto PM Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? J Gen Intern Med 1996;11: 625–34.

Yamamoto K Burnett J Jr Jougasaki M Nishimura RA Bailey KR Saito Y Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28: 988–94.

Talwar S Siebenhofer A Williams B Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N-terminal pro-BNP. Heart 2000;83: 278–82.

Tsuji T Imagawa K Masuda H Haraikawa H Shibata K Kono M Stabilization of human brain natriuretic peptide in blood samples. Clin Chem 1994;40: 672–3.

Murdoch DR Byrne J Morton JJ McDonagh TA Robh SD Clements S Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997;78: 594–7.

Davidson NC Coutie W Struthers AD . N-terminal pro-ANP and BNP are stable for up to 6 hours in whole blood in vitro. Circulation 1995;91: 1276–7.

Sagnella GA . Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998;95: 519–29.

Troughton RW Frampton CW Yandle TG Espiner EA Nicholls MG Richards AM . Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (BNP) concentrations. Lancet 2000;355: 1126–30.

Nousiainen T Jantunen E Vanninen E Remes J Vuolteenaho O Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999;62: 135–41.

Ikeda T Matsuda K Itoh H Shirakami A Miyamato Y Yoshimasa T Plasma levels of brain and atrial natriuretic peptides elevate in proportion to the left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997;133: 307–14.

El-Gamel A Yonan NA Keevil B Warburton R Kakedellis J Woodcock A Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 1997;63: 1095–100.